Adrienne Graves, PhD

Dr. Adrienne Graves is a visual scientist by training and a global industry leader in ophthalmology. Dr. Graves was CEO of Santen Inc (2002-2010) following 7 years there as Sr VP of Worldwide Clinical Development. She previously spent 9 years at Alcon, where she built a Retinal Electrophysiology Lab, directed clinical development and served as Director of International Ophthalmology. Dr. Graves was Chairman of the Board at Iveric Bio until their 2023 acquisition by Astellas, and is currently on the Board of Directors at Ocular Therapeutix, Harrow, Opus Genetics, Qlaris Bio, Surface Ophthalmics, NVasc, JelliSee, and Implandata. She previously held board positions at Nicox (2014-2024), Encore Vision (acquired by Novartis), Envisia (assets acquired by Aerie), TearLab (now Trukera), Aerpio, and Akorn. Dr. Graves also serves on the boards of the following Foundations: American Society of Cataract and Refractive Surgeons (ASCRS), Glaucoma Research Foundation (GRF), American Academy of Ophthalmology (AAO; Emeritus), Retina Global, Himalayan Cataract Project, Foundation Fighting Blindness (FFB), and was a founding board member of OWL (Ophthalmic World Leaders, formerly Ophthalmic Women Leaders). She is Chairman of the RD (Retinal Degeneration) Fund, the venture arm of FFB, and she Co-founded Glaucoma 360. Her recent honors include the Visionary Award (FFB), Catalyst Award (GRF), Visionary Award (OWL), Bernice Brown Memorial Lecture Award (Women in Ophthalmology), and The Ophthalmologist 2021 and 2023 Power Lists. Dr. Graves received an AB with Honors in Psychology from Brown University, a Ph.D. in Pyschobiology/Neuroscience from the University of Michigan, and she completed a Postdoctoral Fellowship in Visual Neuroscience at the University of Paris. She is a Visionary Innovation Mentor for the Ophthalmic Innovation Program at Stanford.